<article article-type="letter"><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Br. J. Cancer</journal-id><journal-title-group><journal-title>British Journal of Cancer</journal-title></journal-title-group><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23764750</article-id><article-id pub-id-type="pmc">3708572</article-id><article-id pub-id-type="pii">bjc2013282</article-id><article-id pub-id-type="doi">10.1038/bjc.2013.282</article-id><article-categories><subj-group subj-group-type="heading"><subject>Short Communication</subject></subj-group></article-categories><title-group><article-title>Does thyroid-stimulating hormone influence the prognosis of patients with endometrial cancer? A multicentre trial</article-title><alt-title alt-title-type="running">Thyroid-stimulating hormone in endometrial cancer</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Seebacher</surname><given-names>V</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Hofstetter</surname><given-names>G</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Polterauer</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Reinthaller</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Grimm</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Schwameis</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Taucher</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Wagener</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Marth</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Concin</surname><given-names>N</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="caf1">*</xref></contrib><aff id="aff1"><label>1</label><institution>Department of Gynaecology and Gynaecological Oncology, Comprehensive Cancer Centre Vienna, Medical University of Vienna, Waehringer Guertel 18-20</institution>, 1090 Vienna, <country>Austria</country></aff><aff id="aff2"><label>2</label><institution>Department of Obstetrics and Gynaecology, Innsbruck Medical University</institution>, Anichstrasse 33, 6020 Innsbruck, <country>Austria</country></aff></contrib-group><author-notes><corresp id="caf1"><label>*</label>E-mail: <email>nicole.concin@i-med.ac.at</email></corresp></author-notes><pub-date pub-type="ppub"><day>09</day><month>07</month><year>2013</year></pub-date><pub-date pub-type="epub"><day>13</day><month>06</month><year>2013</year></pub-date><volume>109</volume><issue>1</issue><fpage>215</fpage><lpage>218</lpage><history><date date-type="received"><day>28</day><month>02</month><year>2013</year></date><date date-type="rev-recd"><day>03</day><month>05</month><year>2013</year></date><date date-type="accepted"><day>10</day><month>05</month><year>2013</year></date></history><permissions><copyright-statement>Copyright Â© 2013 Cancer Research UK</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>Cancer Research UK</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0/"><license-p>From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/</license-p></license></permissions><abstract><sec><title><offsets xml_i="4310" xml_f="4321" txt_i="11" txt_f="22">Background:</offsets></title><p><offsets xml_i="4332" xml_f="4614" txt_i="23" txt_f="305">Thyroid function has been suggested to interfere with tumour biology and prognosis in different cancers. The present study was performed to investigate the impact of pre-therapeutic serum thyroid-stimulating hormone (TSH) levels on the prognosis of patients with endometrial cancer.</offsets></p></sec><sec><title><offsets xml_i="4636" xml_f="4644" txt_i="307" txt_f="315">Methods:</offsets></title><p><offsets xml_i="4655" xml_f="4842" txt_i="316" txt_f="503">Pre-therapeutic serum TSH was investigated in 199 patients with endometrial cancer. After stratification in TSH risk groups, univariate and multivariable survival analyses were performed.</offsets></p></sec><sec><title><offsets xml_i="4864" xml_f="4872" txt_i="505" txt_f="513">Results:</offsets></title><p><offsets xml_i="4883" xml_f="5008" txt_i="514" txt_f="639">Elevated TSH was independently associated with poor disease-specific survival in univariate/multivariable survival analyses (</offsets><italic><offsets xml_i="5016" xml_f="5017" txt_i="639" txt_f="640">P</offsets></italic><offsets xml_i="5026" xml_f="5036" txt_i="640" txt_f="650">=0.01 and </offsets><italic><offsets xml_i="5044" xml_f="5045" txt_i="650" txt_f="651">P</offsets></italic><offsets xml_i="5054" xml_f="5075" txt_i="651" txt_f="672">=0.03, respectively).</offsets></p></sec><sec><title><offsets xml_i="5097" xml_f="5108" txt_i="674" txt_f="685">Conclusion:</offsets></title><p><offsets xml_i="5119" xml_f="5271" txt_i="686" txt_f="838">Thyroid-stimulating hormone may serve as a novel and independent prognostic parameter for disease-specific survival in patients with endometrial cancer.</offsets></p></sec></abstract><kwd-group><kwd>thyroid-stimulating hormone</kwd><kwd>hypothyroidism</kwd><kwd>endometrial cancer</kwd><kwd>prognosis</kwd><kwd>survival</kwd><kwd>thyroid gland</kwd></kwd-group></article-meta></front><body><p><offsets xml_i="5502" xml_f="5783" txt_i="847" txt_f="1128">The thyroid gland's integrity is of decisive importance for the metabolic activity and function of nearly every organ system in adults. Experimental and clinical studies suggest a possible interaction between thyroid function and tumour biology and prognosis in different cancers (</offsets><xref ref-type="bibr" rid="bib4"><offsets xml_i="5816" xml_f="5826" txt_i="1128" txt_f="1138">Hercbergs </offsets><italic><offsets xml_i="5834" xml_f="5839" txt_i="1138" txt_f="1143">et al</offsets></italic><offsets xml_i="5848" xml_f="5854" txt_i="1143" txt_f="1149">, 2003</offsets></xref><offsets xml_i="5861" xml_f="5863" txt_i="1149" txt_f="1151">; </offsets><xref ref-type="bibr" rid="bib16"><offsets xml_i="5897" xml_f="5902" txt_i="1151" txt_f="1156">Tang </offsets><italic><offsets xml_i="5910" xml_f="5915" txt_i="1156" txt_f="1161">et al</offsets></italic><offsets xml_i="5924" xml_f="5930" txt_i="1161" txt_f="1167">, 2004</offsets></xref><offsets xml_i="5937" xml_f="5939" txt_i="1167" txt_f="1169">; </offsets><xref ref-type="bibr" rid="bib3"><offsets xml_i="5972" xml_f="5986" txt_i="1169" txt_f="1183">Cristofanilli </offsets><italic><offsets xml_i="5994" xml_f="5999" txt_i="1183" txt_f="1188">et al</offsets></italic><offsets xml_i="6008" xml_f="6014" txt_i="1188" txt_f="1194">, 2005</offsets></xref><offsets xml_i="6021" xml_f="6023" txt_i="1194" txt_f="1196">; </offsets><xref ref-type="bibr" rid="bib11"><offsets xml_i="6057" xml_f="6064" txt_i="1196" txt_f="1203">Nelson </offsets><italic><offsets xml_i="6072" xml_f="6077" txt_i="1203" txt_f="1208">et al</offsets></italic><offsets xml_i="6086" xml_f="6092" txt_i="1208" txt_f="1214">, 2006</offsets></xref><offsets xml_i="6099" xml_f="6101" txt_i="1214" txt_f="1216">; </offsets><xref ref-type="bibr" rid="bib13"><offsets xml_i="6135" xml_f="6147" txt_i="1216" txt_f="1228">Schmidinger </offsets><italic><offsets xml_i="6155" xml_f="6160" txt_i="1228" txt_f="1233">et al</offsets></italic><offsets xml_i="6169" xml_f="6175" txt_i="1233" txt_f="1239">, 2011</offsets></xref><offsets xml_i="6182" xml_f="6184" txt_i="1239" txt_f="1241">).</offsets></p><p><offsets xml_i="6191" xml_f="6525" txt_i="1242" txt_f="1576">Hypothyroidism, either clinically overt or subclinical, is a common disorder, especially in middle-aged and elderly women. Being defined as commonly encountered comorbidities in patients with endometrial cancer, increased body mass index and age are positively associated with elevated serum thyroid-stimulating hormone (TSH) levels (</offsets><xref ref-type="bibr" rid="bib8"><offsets xml_i="6558" xml_f="6566" txt_i="1576" txt_f="1584">Knudsen </offsets><italic><offsets xml_i="6574" xml_f="6579" txt_i="1584" txt_f="1589">et al</offsets></italic><offsets xml_i="6588" xml_f="6594" txt_i="1589" txt_f="1595">, 2005</offsets></xref><offsets xml_i="6601" xml_f="6603" txt_i="1595" txt_f="1597">; </offsets><xref ref-type="bibr" rid="bib5"><offsets xml_i="6636" xml_f="6642" txt_i="1597" txt_f="1603">Iqbal </offsets><italic><offsets xml_i="6650" xml_f="6655" txt_i="1603" txt_f="1608">et al</offsets></italic><offsets xml_i="6664" xml_f="6670" txt_i="1608" txt_f="1614">, 2006</offsets></xref><offsets xml_i="6677" xml_f="6811" txt_i="1614" txt_f="1748">). Moreover, it is in patients with endometrial cancer that higher serum TSH levels have been found when compared with healthy women (</offsets><xref ref-type="bibr" rid="bib7"><offsets xml_i="6844" xml_f="6857" txt_i="1748" txt_f="1761">Kanat-Pektas </offsets><italic><offsets xml_i="6865" xml_f="6870" txt_i="1761" txt_f="1766">et al</offsets></italic><offsets xml_i="6879" xml_f="6885" txt_i="1766" txt_f="1772">, 2010</offsets></xref><offsets xml_i="6892" xml_f="6894" txt_i="1772" txt_f="1774">).</offsets></p><p><offsets xml_i="6901" xml_f="7059" txt_i="1775" txt_f="1933">The present multicentre trial aims to evaluate the association between pre-therapeutic serum TSH levels and the prognosis in patients with endometrial cancer.</offsets></p><sec sec-type="materials|methods"><title><offsets xml_i="7104" xml_f="7125" txt_i="1934" txt_f="1955">Materials and methods</offsets></title><sec><title><offsets xml_i="7145" xml_f="7153" txt_i="1956" txt_f="1964">Patients</offsets></title><p><offsets xml_i="7164" xml_f="7363" txt_i="1965" txt_f="2164">A total of 199 patients with endometrial cancer were included in the present Austrian multicentre trial (Department of Gynaecology and Gynaecological Oncology, Medical University of Vienna, Austria, </offsets><italic><offsets xml_i="7371" xml_f="7372" txt_i="2164" txt_f="2165">n</offsets></italic><offsets xml_i="7381" xml_f="7467" txt_i="2165" txt_f="2251">=92; Department of Gynaecology and Obstetrics, Medical University Innsbruck, Austria, </offsets><italic><offsets xml_i="7475" xml_f="7476" txt_i="2251" txt_f="2252">n</offsets></italic><offsets xml_i="7485" xml_f="7785" txt_i="2252" txt_f="2552">=107). Clinical and laboratory data were extracted from the respective electronic gynaecologic oncology registries. Patients who did not receive standardised treatment because of age or significant comorbidities, and patients with additional, coexisting malignant disease were excluded from analysis.</offsets></p></sec><sec><title><offsets xml_i="7807" xml_f="7826" txt_i="2554" txt_f="2573">Clinical management</offsets></title><p><offsets xml_i="7837" xml_f="8079" txt_i="2574" txt_f="2816">Patients were surgically staged according to the International Federation of Gynecology and Obstetrics (FIGO)/American Joint Committee on Cancer (AJCC) classification system of FIGO 6th annual report 2006, using the 1988 FIGO classification (</offsets><xref ref-type="bibr" rid="bib2"><offsets xml_i="8112" xml_f="8121" txt_i="2816" txt_f="2825">Creasman </offsets><italic><offsets xml_i="8129" xml_f="8134" txt_i="2825" txt_f="2830">et al</offsets></italic><offsets xml_i="8143" xml_f="8149" txt_i="2830" txt_f="2836">, 2006</offsets></xref><offsets xml_i="8156" xml_f="8258" txt_i="2836" txt_f="2938">). Patients were treated and followed according to international guidelines, as described previously (</offsets><xref ref-type="bibr" rid="bib14"><offsets xml_i="8292" xml_f="8302" txt_i="2938" txt_f="2948">Seebacher </offsets><italic><offsets xml_i="8310" xml_f="8315" txt_i="2948" txt_f="2953">et al</offsets></italic><offsets xml_i="8324" xml_f="8330" txt_i="2953" txt_f="2959">, 2010</offsets></xref><offsets xml_i="8337" xml_f="8339" txt_i="2959" txt_f="2961">).</offsets></p><p><offsets xml_i="8346" xml_f="8572" txt_i="2962" txt_f="3188">Recurrent disease was either diagnosed by biopsy or by imaging methods, following standard clinical guidelines. If patients did not present for scheduled follow-up visits, the administrative personnel or nurses contacted them.</offsets></p></sec><sec><title><offsets xml_i="8594" xml_f="8609" txt_i="3190" txt_f="3205">TSH measurement</offsets></title><p><offsets xml_i="8620" xml_f="8852" txt_i="3206" txt_f="3438">Blood samples (serum) were obtained routinely by peripheral venous puncture before therapy during pretreatment examination. According to recommendations of the National Academy of Clinical Biochemistry, a TSH serum level of 2.5âmUâl</offsets><sup><offsets xml_i="8857" xml_f="8859" txt_i="3438" txt_f="3440">â1</offsets></sup><offsets xml_i="8865" xml_f="8940" txt_i="3440" txt_f="3515"> was considered as upper limit of normal of the euthyroid reference range (</offsets><xref ref-type="bibr" rid="bib1"><offsets xml_i="8973" xml_f="8980" txt_i="3515" txt_f="3522">Baloch </offsets><italic><offsets xml_i="8988" xml_f="8993" txt_i="3522" txt_f="3527">et al</offsets></italic><offsets xml_i="9002" xml_f="9008" txt_i="3527" txt_f="3533">, 2003</offsets></xref><offsets xml_i="9015" xml_f="9017" txt_i="3533" txt_f="3535">).</offsets></p></sec><sec><title><offsets xml_i="9039" xml_f="9059" txt_i="3537" txt_f="3557">Statistical analysis</offsets></title><p><offsets xml_i="9070" xml_f="9316" txt_i="3558" txt_f="3804">Values are given as number (percentage) or median (minimumâmaximum) as appropriate. KruskalâWallis one-way analysis of variance was used to assess the association between the medians of pretreatment serum TSH and clinicalâpathological parameters.</offsets></p><p><offsets xml_i="9323" xml_f="9472" txt_i="3805" txt_f="3954">For survival analysis, patients were assigned to two prognostic groups according to their pre-therapeutic serum TSH levels as follows: TSH â©½ 2.5âmUâl</offsets><sup><offsets xml_i="9477" xml_f="9479" txt_i="3954" txt_f="3956">â1</offsets></sup><offsets xml_i="9485" xml_f="9519" txt_i="3956" txt_f="3987"> (normal low) and TSH &gt;2.5âmUâl</offsets><sup><offsets xml_i="9524" xml_f="9526" txt_i="3987" txt_f="3989">â1</offsets></sup><offsets xml_i="9532" xml_f="10176" txt_i="3989" txt_f="4633"> (elevated). Survival probabilities were calculated by the product limit method of Kaplan and Meier. Differences between groups were tested using the log-rank test. The results were analysed for the end point of disease-free and disease-specific survival. Events were defined as first diagnosis of recurrent disease or cancer-related death at the time of the last follow-up visit, respectively. Patients who died of other causes than endometrial cancer or patients alive were censored with the date of death or last follow-up, respectively. Univariate and multivariable Cox regression models were performed, comprising the TSH groups (elevated </offsets><italic><offsets xml_i="10184" xml_f="10186" txt_i="4633" txt_f="4635">vs</offsets></italic><offsets xml_i="10195" xml_f="10236" txt_i="4635" txt_f="4676"> normal low), FIGO tumour stage (FIGO IV </offsets><italic><offsets xml_i="10244" xml_f="10246" txt_i="4676" txt_f="4678">vs</offsets></italic><offsets xml_i="10255" xml_f="10265" txt_i="4678" txt_f="4688"> FIGO III </offsets><italic><offsets xml_i="10273" xml_f="10275" txt_i="4688" txt_f="4690">vs</offsets></italic><offsets xml_i="10284" xml_f="10293" txt_i="4690" txt_f="4699"> FIGO II </offsets><italic><offsets xml_i="10301" xml_f="10303" txt_i="4699" txt_f="4701">vs</offsets></italic><offsets xml_i="10312" xml_f="10345" txt_i="4701" txt_f="4734"> FIGO I), histological grade (G3 </offsets><italic><offsets xml_i="10353" xml_f="10355" txt_i="4734" txt_f="4736">vs</offsets></italic><offsets xml_i="10364" xml_f="10368" txt_i="4736" txt_f="4740"> G2 </offsets><italic><offsets xml_i="10376" xml_f="10378" txt_i="4740" txt_f="4742">vs</offsets></italic><offsets xml_i="10387" xml_f="10430" txt_i="4742" txt_f="4782"> G1), and the patients' mean age (&gt;66.5 </offsets><italic><offsets xml_i="10438" xml_f="10440" txt_i="4782" txt_f="4784">vs</offsets></italic><offsets xml_i="10449" xml_f="10535" txt_i="4784" txt_f="4870"> â©½66.5 years). Results of univariate and multivariable survival analyses are given as </offsets><italic><offsets xml_i="10543" xml_f="10544" txt_i="4870" txt_f="4871">P</offsets></italic><offsets xml_i="10553" xml_f="10622" txt_i="4871" txt_f="4940">-value (hazard ratio (HR) and 95% confidence interval (95% CI)). The </offsets><italic><offsets xml_i="10630" xml_f="10631" txt_i="4940" txt_f="4941">P</offsets></italic><offsets xml_i="10640" xml_f="10845" txt_i="4941" txt_f="5143">-values of &lt;0.05 were considered statistically significant. We used the statistical software SPSS 20.0 for Mac (IBM SPSS Statistics 20.0.0, IBM Germany GmbH, Ehningen, Germany) for statistical analysis.</offsets></p></sec><sec><title><offsets xml_i="10867" xml_f="10893" txt_i="5145" txt_f="5171">Institutional review board</offsets></title><p><offsets xml_i="10904" xml_f="11126" txt_i="5172" txt_f="5394">The present trial was approved by the institutional review boards, that is, the Ethics-Committees of the Medical University of Vienna (Project 248/2009, 21-04-2009), as well as of the Medical University Innsbruck (UN4144).</offsets></p></sec></sec><sec sec-type="results"><title><offsets xml_i="11173" xml_f="11180" txt_i="5397" txt_f="5404">Results</offsets></title><sec><title><offsets xml_i="11200" xml_f="11236" txt_i="5405" txt_f="5441">Clinical characteristics of patients</offsets></title><p><offsets xml_i="11247" xml_f="11308" txt_i="5442" txt_f="5503">Clinical characteristics of recruited patients are listed in </offsets><xref ref-type="supplementary-material" rid="sup1"><offsets xml_i="11359" xml_f="11380" txt_i="5503" txt_f="5524">Supplementary Table 3</offsets></xref><offsets xml_i="11387" xml_f="11475" txt_i="5524" txt_f="5612">. The median (minimumâmaximum) pre-therapeutic serum TSH level was 1.27 (0.01â14.8) mUâl</offsets><sup><offsets xml_i="11480" xml_f="11482" txt_i="5612" txt_f="5614">â1</offsets></sup><offsets xml_i="11488" xml_f="11604" txt_i="5614" txt_f="5727">. In all, 173 patients (86.9%) and 26 patients (13.1%) showed pre-therapeutic serum TSH levels â©½2.5 and &gt;2.5âmUâl</offsets><sup><offsets xml_i="11609" xml_f="11611" txt_i="5727" txt_f="5729">â1</offsets></sup><offsets xml_i="11617" xml_f="12042" txt_i="5729" txt_f="6154">, respectively. As far as data were available, 70.2% of patients presented with obesity, 63.6% with hypertension, and 32% with diabetes mellitus. Lymph node status was available in 111 patients. Lymph node involvement was noted in 27 patients (13.6%). Radiotherapy was performed in 103 patients and chemotherapy in 34 patients. Patients' characteristics were distributed equally within the two study centres (data not shown).</offsets></p></sec><sec><title><offsets xml_i="12064" xml_f="12124" txt_i="6156" txt_f="6216">Association between TSH and clinicalâpathological parameters</offsets></title><p><offsets xml_i="12135" xml_f="12240" txt_i="6217" txt_f="6322">No association could be found between elevated pre-therapeutic serum TSH and advanced FIGO tumour stage (</offsets><italic><offsets xml_i="12248" xml_f="12249" txt_i="6322" txt_f="6323">P</offsets></italic><offsets xml_i="12258" xml_f="12290" txt_i="6323" txt_f="6355">=0.6), high histological grade (</offsets><italic><offsets xml_i="12298" xml_f="12299" txt_i="6355" txt_f="6356">P</offsets></italic><offsets xml_i="12308" xml_f="12350" txt_i="6356" txt_f="6398">=0.8), unfavourable histological subtype (</offsets><italic><offsets xml_i="12358" xml_f="12359" txt_i="6398" txt_f="6399">P</offsets></italic><offsets xml_i="12368" xml_f="12394" txt_i="6399" txt_f="6425">=0.9), older patient age (</offsets><italic><offsets xml_i="12402" xml_f="12403" txt_i="6425" txt_f="6426">P</offsets></italic><offsets xml_i="12412" xml_f="12457" txt_i="6426" txt_f="6471">=0.5), or lifestyle factors such as obesity (</offsets><italic><offsets xml_i="12465" xml_f="12466" txt_i="6471" txt_f="6472">P</offsets></italic><offsets xml_i="12475" xml_f="12496" txt_i="6472" txt_f="6493">=0.4), hypertension (</offsets><italic><offsets xml_i="12504" xml_f="12505" txt_i="6493" txt_f="6494">P</offsets></italic><offsets xml_i="12514" xml_f="12543" txt_i="6494" txt_f="6523">=0.9), or diabetes mellitus (</offsets><italic><offsets xml_i="12551" xml_f="12552" txt_i="6523" txt_f="6524">P</offsets></italic><offsets xml_i="12561" xml_f="12567" txt_i="6524" txt_f="6530">=0.5).</offsets></p></sec><sec><title><offsets xml_i="12589" xml_f="12625" txt_i="6532" txt_f="6568">Association between TSH and survival</offsets></title><p><offsets xml_i="12636" xml_f="12825" txt_i="6569" txt_f="6758">Results on the 5-year disease-free and disease-specific survival stratified for FIGO tumour stage, histological grade, histological subtype, patients' age, and TSH risk groups are shown in </offsets><xref rid="tbl1" ref-type="table"><offsets xml_i="12859" xml_f="12866" txt_i="6758" txt_f="6765">Table 1</offsets></xref><offsets xml_i="12873" xml_f="13183" txt_i="6765" txt_f="7075">. In univariate analysis, the elevated TSH risk group was associated with poor disease-free and disease-specific survival. In multivariable analysis, the elevated TSH risk group was independently association with poor disease-specific survival. Results of univariate and multivariable analyses are provided in </offsets><xref rid="tbl1" ref-type="table"><offsets xml_i="13217" xml_f="13225" txt_i="7075" txt_f="7083">Tables 1</offsets></xref><offsets xml_i="13232" xml_f="13237" txt_i="7083" txt_f="7088"> and </offsets><xref rid="tbl2" ref-type="table"><offsets xml_i="13271" xml_f="13272" txt_i="7088" txt_f="7089">2</offsets></xref><offsets xml_i="13279" xml_f="13295" txt_i="7089" txt_f="7105">, respectively. </offsets><xref ref-type="fig" rid="fig1"><offsets xml_i="13327" xml_f="13335" txt_i="7105" txt_f="7113">Figure 1</offsets></xref><offsets xml_i="13342" xml_f="13396" txt_i="7113" txt_f="7167"> shows KaplanâMeier curves for TSH groups (normal low </offsets><italic><offsets xml_i="13404" xml_f="13406" txt_i="7167" txt_f="7169">vs</offsets></italic><offsets xml_i="13415" xml_f="13465" txt_i="7169" txt_f="7219"> elevated) according to disease-specific survival.</offsets></p></sec></sec><sec sec-type="discussion"><title><offsets xml_i="13515" xml_f="13525" txt_i="7222" txt_f="7232">Discussion</offsets></title><p><offsets xml_i="13536" xml_f="13960" txt_i="7233" txt_f="7657">The present multicentre trial investigates the influence of TSH on the prognosis of patients with endometrial cancer. Present data demonstrate an independent association between elevated pre-therapeutic serum TSH levels and poor disease-specific survival in patients with endometrial cancer. These findings are interesting from the clinical point of view, as hypothyroidism is a common disorder, especially in elderly women.</offsets></p><p><offsets xml_i="13967" xml_f="14083" txt_i="7658" txt_f="7774">Similar to results by previous authors, serum TSH levels were not associated with clinicalâpathological parameters (</offsets><xref ref-type="bibr" rid="bib7"><offsets xml_i="14116" xml_f="14129" txt_i="7774" txt_f="7787">Kanat-Pektas </offsets><italic><offsets xml_i="14137" xml_f="14142" txt_i="7787" txt_f="7792">et al</offsets></italic><offsets xml_i="14151" xml_f="14157" txt_i="7792" txt_f="7798">, 2010</offsets></xref><offsets xml_i="14164" xml_f="14607" txt_i="7798" txt_f="8241">). This finding could suggest that TSH might be associated with systemic processes interacting with carcinogenesis, for example, hormonal imbalance or inflammation, rather than with the local neoplastic transformation. Previously published studies reported on an association between lifestyle factors, such as obesity, hypertension, and diabetes mellitus, and thyroid function. These factors were found to be unrelated with TSH in this study (</offsets><xref ref-type="bibr" rid="bib8"><offsets xml_i="14640" xml_f="14648" txt_i="8241" txt_f="8249">Knudsen </offsets><italic><offsets xml_i="14656" xml_f="14661" txt_i="8249" txt_f="8254">et al</offsets></italic><offsets xml_i="14670" xml_f="14676" txt_i="8254" txt_f="8260">, 2005</offsets></xref><offsets xml_i="14683" xml_f="14685" txt_i="8260" txt_f="8262">; </offsets><xref ref-type="bibr" rid="bib5"><offsets xml_i="14718" xml_f="14724" txt_i="8262" txt_f="8268">Iqbal </offsets><italic><offsets xml_i="14732" xml_f="14737" txt_i="8268" txt_f="8273">et al</offsets></italic><offsets xml_i="14746" xml_f="14752" txt_i="8273" txt_f="8279">, 2006</offsets></xref><offsets xml_i="14759" xml_f="14761" txt_i="8279" txt_f="8281">).</offsets></p><p><offsets xml_i="14768" xml_f="15110" txt_i="8282" txt_f="8624">Thyroid disorders have previously been associated with the prognosis in cancer. Yet, hypothyroidism seems to have various effects on different types of cancer. While improving treatment outcome of head and neck cancer, glioma, and breast cancer, high serum TSH levels were associated with poor survival in patients with renal cell carcinoma (</offsets><xref ref-type="bibr" rid="bib4"><offsets xml_i="15143" xml_f="15153" txt_i="8624" txt_f="8634">Hercbergs </offsets><italic><offsets xml_i="15161" xml_f="15166" txt_i="8634" txt_f="8639">et al</offsets></italic><offsets xml_i="15175" xml_f="15181" txt_i="8639" txt_f="8645">, 2003</offsets></xref><offsets xml_i="15188" xml_f="15190" txt_i="8645" txt_f="8647">; </offsets><xref ref-type="bibr" rid="bib3"><offsets xml_i="15223" xml_f="15237" txt_i="8647" txt_f="8661">Cristofanilli </offsets><italic><offsets xml_i="15245" xml_f="15250" txt_i="8661" txt_f="8666">et al</offsets></italic><offsets xml_i="15259" xml_f="15265" txt_i="8666" txt_f="8672">, 2005</offsets></xref><offsets xml_i="15272" xml_f="15274" txt_i="8672" txt_f="8674">; </offsets><xref ref-type="bibr" rid="bib11"><offsets xml_i="15308" xml_f="15315" txt_i="8674" txt_f="8681">Nelson </offsets><italic><offsets xml_i="15323" xml_f="15328" txt_i="8681" txt_f="8686">et al</offsets></italic><offsets xml_i="15337" xml_f="15343" txt_i="8686" txt_f="8692">, 2006</offsets></xref><offsets xml_i="15350" xml_f="15352" txt_i="8692" txt_f="8694">; </offsets><xref ref-type="bibr" rid="bib13"><offsets xml_i="15386" xml_f="15398" txt_i="8694" txt_f="8706">Schmidinger </offsets><italic><offsets xml_i="15406" xml_f="15411" txt_i="8706" txt_f="8711">et al</offsets></italic><offsets xml_i="15420" xml_f="15426" txt_i="8711" txt_f="8717">, 2011</offsets></xref><offsets xml_i="15433" xml_f="15588" txt_i="8717" txt_f="8872">). This inconsistency might reflect differences in tumour genesis between endometrial and other types of cancer as well as a multifunctional nature of TSH.</offsets></p><p><offsets xml_i="15595" xml_f="15860" txt_i="8873" txt_f="9138">A strong interaction between the hypothalamusâpituitaryâthyroid axis and the balanced secretion of estradiol and progesterone by granulosa cells is well known. Hypothyroidism interferes with ovarian function, causing the formation of ovarian cysts and infertility (</offsets><xref ref-type="bibr" rid="bib15"><offsets xml_i="15894" xml_f="15914" txt_i="9138" txt_f="9158">Stavreus-Evers, 2012</offsets></xref><offsets xml_i="15921" xml_f="16243" txt_i="9158" txt_f="9480">). In patients with polycystic ovarian syndrome (PCOS), a higher prevalence of hypothyroidism has been demonstrated. Hypothyroidism thereby seems to worsen PCOS by decreasing the levels of sex hormone-binding globulin and by increasing the conversion of androstenedione to testosterone and its aromatisation to estradiol (</offsets><xref ref-type="bibr" rid="bib6"><offsets xml_i="16276" xml_f="16284" txt_i="9480" txt_f="9488">Janssen </offsets><italic><offsets xml_i="16292" xml_f="16297" txt_i="9488" txt_f="9493">et al</offsets></italic><offsets xml_i="16306" xml_f="16312" txt_i="9493" txt_f="9499">, 2004</offsets></xref><offsets xml_i="16319" xml_f="16491" txt_i="9499" txt_f="9671">). Without adequate opposition by a progestin, the incurred chronic excess exposure to endogenous estradiol constitutes one of the main risk factors for endometrial cancer.</offsets></p><p><offsets xml_i="16498" xml_f="16716" txt_i="9672" txt_f="9890">Another effect of TSH on adipose tissue is the release of leptin. Besides regulating energy homeostasis and neuroendocrine processes, leptin acts as a potential growth stimulator in normal and neoplastic cancer cells (</offsets><xref ref-type="bibr" rid="bib10"><offsets xml_i="16750" xml_f="16759" txt_i="9890" txt_f="9899">Menendez </offsets><italic><offsets xml_i="16767" xml_f="16772" txt_i="9899" txt_f="9904">et al</offsets></italic><offsets xml_i="16781" xml_f="16787" txt_i="9904" txt_f="9910">, 2003</offsets></xref><offsets xml_i="16794" xml_f="16946" txt_i="9910" txt_f="10062">). Recent studies suggest a role of leptin in promoting endometrial cancer growth and invasion by regulating proangiogenic and proinflammatory factors (</offsets><xref ref-type="bibr" rid="bib9"><offsets xml_i="16979" xml_f="16983" txt_i="10062" txt_f="10066">Liu </offsets><italic><offsets xml_i="16991" xml_f="16996" txt_i="10066" txt_f="10071">et al</offsets></italic><offsets xml_i="17005" xml_f="17011" txt_i="10071" txt_f="10077">, 2011</offsets></xref><offsets xml_i="17018" xml_f="17125" txt_i="10077" txt_f="10184">). In human breast cancer cells, overlapping actions of estrogen and thyroid hormones on estrogen receptor-</offsets><italic><offsets xml_i="17133" xml_f="17134" txt_i="10184" txt_f="10185">Î±</offsets></italic><offsets xml_i="17143" xml_f="17220" txt_i="10185" txt_f="10262"> and thereby stimulation of breast cancer cell growth could be demonstrated (</offsets><xref ref-type="bibr" rid="bib16"><offsets xml_i="17254" xml_f="17259" txt_i="10262" txt_f="10267">Tang </offsets><italic><offsets xml_i="17267" xml_f="17272" txt_i="10267" txt_f="10272">et al</offsets></italic><offsets xml_i="17281" xml_f="17287" txt_i="10272" txt_f="10278">, 2004</offsets></xref><offsets xml_i="17294" xml_f="17433" txt_i="10278" txt_f="10417">). As it has been shown that human endometrium expresses TSH receptors, it has been hypothesised that TSH can even directly act on uterus (</offsets><xref ref-type="bibr" rid="bib12"><offsets xml_i="17467" xml_f="17493" txt_i="10417" txt_f="10443">Poppe and Velkeniers, 2004</offsets></xref><offsets xml_i="17500" xml_f="17667" txt_i="10443" txt_f="10610">). Whether TSH possesses a direct biological role in tumour genesis of endometrial cancer or is indirectly promoting cancer development and progression is yet unclear.</offsets></p><p><offsets xml_i="17674" xml_f="18089" txt_i="10611" txt_f="11026">This analysis uses data from two large gynaecological cancer centres. Although multicentre data repositories offer the opportunity to narrow study bias, there are several limitations inherent to retrospective study design. Hence, the results of our study are shortened by a lack of random assignment, patient selection, and incomplete data acquisition even though prospectively maintained data bases were extracted.</offsets></p><p><offsets xml_i="18096" xml_f="19068" txt_i="11027" txt_f="11999">To our knowledge, this study is the first to investigate the association between pre-therapeutic serum TSH levels and the prognosis in patients with endometrial cancer. These findings, if proven by larger prospective studies, could have major clinical implications. For instance, serum TSH measurements may be used to screen women who are at high risk for endometrial cancer. Another implication may be the utilisation of serum TSH measurements for determination of recurrences during the clinical follow-up. By elucidating the value of TSH as independent prognostic parameter for survival in patients with endometrial cancer, our results provide new insight in possible functional properties of TSH and reflect the yet insufficiently explored impact of hormonal imbalance on the nature and cause of cancer. Further research should be focussed on clinical utilisation of TSH for prognostic evaluation and the participation of TSH in the pathogenesis of endometrial cancer.</offsets></p></sec></body><back><fn-group><fn><p><xref ref-type="supplementary-material" rid="sup1">Supplementary Information</xref> accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)</p></fn></fn-group><ref-list><ref id="bib1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baloch</surname><given-names>Z</given-names></name><name><surname>Carayon</surname><given-names>P</given-names></name><name><surname>Conte-Devoix</surname><given-names>B</given-names></name><name><surname>Demers</surname><given-names>LM</given-names></name><name><surname>Feldt-Rasmussen</surname><given-names>U</given-names></name><name><surname>Henry</surname><given-names>JF</given-names></name><name><surname>LiVosli</surname><given-names>VA</given-names></name><name><surname>Niccoli-Sire</surname><given-names>P</given-names></name><name><surname>John</surname><given-names>R</given-names></name><name><surname>Ruf</surname><given-names>J</given-names></name><name><surname>Smyth</surname><given-names>PP</given-names></name><name><surname>Spencer</surname><given-names>CA</given-names></name><name><surname>Stockigt</surname><given-names>JR</given-names></name><collab>Guidelines Committee, National Academy of Clinical Biochemistry</collab></person-group><year>2003</year><article-title>Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease</article-title><source>Thyroid</source><volume>13</volume><fpage>3</fpage><lpage>126</lpage><pub-id pub-id-type="pmid">12625976</pub-id></mixed-citation></ref><ref id="bib2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Creasman</surname><given-names>WT</given-names></name><name><surname>Odicino</surname><given-names>F</given-names></name><name><surname>Maisonneuve</surname><given-names>P</given-names></name><name><surname>Quinn</surname><given-names>MA</given-names></name><name><surname>Beller</surname><given-names>U</given-names></name><name><surname>Benedet</surname><given-names>JL</given-names></name><name><surname>Heintz</surname><given-names>AP</given-names></name><name><surname>Ngan</surname><given-names>HY</given-names></name><name><surname>Pecorelli</surname><given-names>S</given-names></name></person-group><year>2006</year><article-title>Carcinoma of the corpus uteri. FIGO 26th annual report on the results of treatment in gynecologic cancer</article-title><source>Int J Gynaecol Obstet</source><volume>95</volume><supplement>(Suppl 1</supplement><fpage>105</fpage><lpage>143</lpage></mixed-citation></ref><ref id="bib3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cristofanilli</surname><given-names>M</given-names></name><name><surname>Yamamura</surname><given-names>Y</given-names></name><name><surname>Kau</surname><given-names>SW</given-names></name><name><surname>Bevers</surname><given-names>T</given-names></name><name><surname>Strom</surname><given-names>S</given-names></name><name><surname>Patangan</surname><given-names>M</given-names></name><name><surname>Hsu</surname><given-names>L</given-names></name><name><surname>Krishnamurthy</surname><given-names>S</given-names></name><name><surname>Theriault</surname><given-names>RL</given-names></name><name><surname>Hortobagyi</surname><given-names>GN</given-names></name></person-group><year>2005</year><article-title>Thyroid hormone and breast carcinoma. Primary hypothyroidism is associated with a reduced incidence of primary breast cancer</article-title><source>Cancer</source><volume>103</volume><fpage>1122</fpage><lpage>1128</lpage><pub-id pub-id-type="pmid">15712375</pub-id></mixed-citation></ref><ref id="bib4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hercbergs</surname><given-names>AA</given-names></name><name><surname>Goyal</surname><given-names>LK</given-names></name><name><surname>Suh</surname><given-names>JH</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Reddy</surname><given-names>CA</given-names></name><name><surname>Cohen</surname><given-names>BH</given-names></name><name><surname>Stevens</surname><given-names>GH</given-names></name><name><surname>Reddy</surname><given-names>SK</given-names></name><name><surname>Peereboom</surname><given-names>DM</given-names></name><name><surname>Elson</surname><given-names>PJ</given-names></name><name><surname>Gupta</surname><given-names>MK</given-names></name><name><surname>Barnett</surname><given-names>GH</given-names></name></person-group><year>2003</year><article-title>Propylthiouracil-induced chemical hypothyroidism with high-dose tamoxifen prolongs survival in recurrent high grade glioma: a phase I/II study</article-title><source>Anticancer Res</source><volume>23</volume><fpage>617</fpage><lpage>626</lpage><pub-id pub-id-type="pmid">12680157</pub-id></mixed-citation></ref><ref id="bib5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iqbal</surname><given-names>A</given-names></name><name><surname>Figenschau</surname><given-names>Y</given-names></name><name><surname>Jorde</surname><given-names>R</given-names></name></person-group><year>2006</year><article-title>Blood pressure in relation to serum thyrotropin: the TromsÃ¸ study</article-title><source>J Human Hypertension</source><volume>20</volume><fpage>932</fpage><lpage>936</lpage></mixed-citation></ref><ref id="bib6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janssen</surname><given-names>OE</given-names></name><name><surname>Mehlmauer</surname><given-names>N</given-names></name><name><surname>Hahn</surname><given-names>S</given-names></name><name><surname>Ãffner</surname><given-names>AH</given-names></name><name><surname>GÃ¤rtner</surname><given-names>R</given-names></name></person-group><year>2004</year><article-title>High prevalence of autoimmune thyroiditis in patients with polycystic ovarian syndrome</article-title><source>Eur J Endocrinol</source><volume>150</volume><fpage>363</fpage><lpage>369</lpage><pub-id pub-id-type="pmid">15012623</pub-id></mixed-citation></ref><ref id="bib7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanat-Pektas</surname><given-names>M</given-names></name><name><surname>Yenicesu</surname><given-names>O</given-names></name><name><surname>Gungor</surname><given-names>T</given-names></name><name><surname>Bilge</surname><given-names>U</given-names></name></person-group><year>2010</year><article-title>Predictive power of sexual hormones and tumor markers in endometrial cancer</article-title><source>Arch Gynecol Obstet</source><volume>281</volume><fpage>709</fpage><lpage>715</lpage><pub-id pub-id-type="pmid">19777250</pub-id></mixed-citation></ref><ref id="bib8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knudsen</surname><given-names>N</given-names></name><name><surname>Laurberg</surname><given-names>P</given-names></name><name><surname>Rasmussen</surname><given-names>LB</given-names></name><name><surname>Bulow</surname><given-names>I</given-names></name><name><surname>Perrild</surname><given-names>H</given-names></name><name><surname>Ovesen</surname><given-names>L</given-names></name><name><surname>JÃ¸rgensen</surname><given-names>T</given-names></name></person-group><year>2005</year><article-title>Small difference in thyroid function may be important for body mass index and the occurrence of obesity in the population</article-title><source>J Clin Endocrinol Metab</source><volume>90</volume><fpage>4019</fpage><lpage>4024</lpage><pub-id pub-id-type="pmid">15870128</pub-id></mixed-citation></ref><ref id="bib9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Lv</surname><given-names>L</given-names></name><name><surname>Xiao</surname><given-names>W</given-names></name><name><surname>Gong</surname><given-names>C</given-names></name><name><surname>Yin</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Sheng</surname><given-names>H</given-names></name></person-group><year>2011</year><article-title>Leptin activates STAT3 and ERK1/2 pathways and induces endometrial cancer cell proliferation</article-title><source>J Huazhong Univ Sci Technolog Med Sci</source><volume>31</volume><fpage>365</fpage><lpage>370</lpage><pub-id pub-id-type="pmid">21671179</pub-id></mixed-citation></ref><ref id="bib10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menendez</surname><given-names>C</given-names></name><name><surname>Baldelli</surname><given-names>R</given-names></name><name><surname>Camina</surname><given-names>JP</given-names></name><name><surname>Escudero</surname><given-names>B</given-names></name><name><surname>Peino</surname><given-names>R</given-names></name><name><surname>Dieguez</surname><given-names>C</given-names></name><name><surname>Casanueva</surname><given-names>FF</given-names></name></person-group><year>2003</year><article-title>TSH stimulates leptin secretion by a direct effect on adipocytes</article-title><source>J Endocrinol</source><volume>176</volume><fpage>7</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">12525244</pub-id></mixed-citation></ref><ref id="bib11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nelson</surname><given-names>M</given-names></name><name><surname>Hercbergs</surname><given-names>A</given-names></name><name><surname>Rybicki</surname><given-names>L</given-names></name><name><surname>Strome</surname><given-names>M</given-names></name></person-group><year>2006</year><article-title>Association between development of hypothyroidism and improved survival in patients with head and neck cancer</article-title><source>Arch Otolaryngol Head Neck Surg</source><volume>132</volume><fpage>1041</fpage><lpage>1046</lpage><pub-id pub-id-type="pmid">17043248</pub-id></mixed-citation></ref><ref id="bib12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poppe</surname><given-names>K</given-names></name><name><surname>Velkeniers</surname><given-names>B</given-names></name></person-group><year>2004</year><article-title>Female infertility and the thyroid</article-title><source>Best Pract Res Clin Endocrinol Metab</source><volume>18</volume><fpage>153</fpage><lpage>165</lpage><pub-id pub-id-type="pmid">15157833</pub-id></mixed-citation></ref><ref id="bib13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidinger</surname><given-names>M</given-names></name><name><surname>Vogl</surname><given-names>UM</given-names></name><name><surname>Bojic</surname><given-names>M</given-names></name><name><surname>Lamm</surname><given-names>W</given-names></name><name><surname>Heinzl</surname><given-names>H</given-names></name><name><surname>Haitel</surname><given-names>A</given-names></name><name><surname>Clodi</surname><given-names>M</given-names></name><name><surname>Kramer</surname><given-names>G</given-names></name><name><surname>Zielinski</surname><given-names>CC</given-names></name></person-group><year>2011</year><article-title>Hypothyroidism in patients with renal cell carcinoma: blessing or curse</article-title><source>Cancer</source><volume>117</volume><fpage>534</fpage><lpage>544</lpage><pub-id pub-id-type="pmid">20845482</pub-id></mixed-citation></ref><ref id="bib14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seebacher</surname><given-names>V</given-names></name><name><surname>Polterauer</surname><given-names>S</given-names></name><name><surname>Grimm</surname><given-names>C</given-names></name><name><surname>Husslein</surname><given-names>H</given-names></name><name><surname>Leipold</surname><given-names>H</given-names></name><name><surname>Hefler-Frischmuth</surname><given-names>K</given-names></name><name><surname>Tempfer</surname><given-names>C</given-names></name><name><surname>Reinthaller</surname><given-names>A</given-names></name><name><surname>Hefler</surname><given-names>L</given-names></name></person-group><year>2010</year><article-title>The prognostic value of plasma fibrinogen levels in patients with endometrial cancer: a multi-centre trial</article-title><source>Br J Cancer</source><volume>16</volume><fpage>952</fpage><lpage>956</lpage><pub-id pub-id-type="pmid">20160724</pub-id></mixed-citation></ref><ref id="bib15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stavreus-Evers</surname><given-names>A</given-names></name></person-group><year>2012</year><article-title></article-title><source>Front Endocrinol (Lausanne)</source><volume>3</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">22649402</pub-id></mixed-citation></ref><ref id="bib16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>HY</given-names></name><name><surname>Lin</surname><given-names>HY</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Davis</surname><given-names>FB</given-names></name><name><surname>Davis</surname><given-names>PJ</given-names></name></person-group><year>2004</year><article-title>Thyroid hormone causes mitogen activated protein kinase-dependent phosphorylation of the nuclear estrogen receptor</article-title><source>Endocrinology</source><volume>145</volume><fpage>3265</fpage><lpage>3272</lpage><pub-id pub-id-type="pmid">15059947</pub-id></mixed-citation></ref></ref-list><sec sec-type="supplementary-material" id="sup1"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="xob1"><label>Supplementary Table</label><media mimetype="application" mime-subtype="vnd.ms-excel" xlink:href="bjc2013282x1.xls"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></back><floats-group><fig id="fig1"><label>Figure 1</label><caption><p><bold>KaplanâMeier curves for pre-therapeutic TSH risk groups ânormal low' (upper line) <italic>vs</italic> âelevated' (lower line) and disease-specific survival (<italic>P</italic>=0.01).</bold></p></caption><graphic xlink:href="bjc2013282f1"></graphic></fig><table-wrap id="tbl1"><label>Table 1</label><caption><title>The 5-year disease-free and disease-specific survival</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"></col><col align="char" char="("></col><col align="char" char="."></col><col align="char" char="("></col><col align="char" char="."></col></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><bold>Parameter</bold></th><th align="center" valign="top" char="(" charoff="50"><bold>The 5-year disease-free survival, % (s.e.)</bold></th><th align="center" valign="top" char="." charoff="50"><italic><bold>P</bold></italic><bold>-value</bold><xref ref-type="fn" rid="t1-fn2">a</xref></th><th align="center" valign="top" char="(" charoff="50"><bold>The 5-year disease-specific survival, % (s.e.)</bold></th><th align="center" valign="top" char="." charoff="50"><italic><bold>P</bold></italic><bold>-value</bold><xref ref-type="fn" rid="t1-fn2">a</xref></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Stage<xref ref-type="fn" rid="t1-fn3">b</xref><hr></hr></td><td align="char" valign="top" char="(" charoff="50">Â <hr></hr></td><td align="char" valign="top" char="." charoff="50">&lt;0.001<hr></hr></td><td align="char" valign="top" char="(" charoff="50">Â <hr></hr></td><td align="char" valign="top" char="." charoff="50">&lt;0.001<hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">FIGO IV</td><td align="char" valign="top" char="(" charoff="50">30.0 (14.5)</td><td align="char" valign="top" char="." charoff="50">Â </td><td align="char" valign="top" char="(" charoff="50">33.3 (15.7)</td><td align="char" valign="top" char="." charoff="50">Â </td></tr><tr><td align="left" valign="top" charoff="50">FIGO III</td><td align="char" valign="top" char="(" charoff="50">45.0 (10.0)</td><td align="char" valign="top" char="." charoff="50">Â </td><td align="char" valign="top" char="(" charoff="50">50.8 (10.8)</td><td align="char" valign="top" char="." charoff="50">Â </td></tr><tr><td align="left" valign="top" charoff="50">FIGO II</td><td align="char" valign="top" char="(" charoff="50">69.8 (14.9)</td><td align="char" valign="top" char="." charoff="50">Â </td><td align="char" valign="top" char="(" charoff="50">90.9 (8.7)</td><td align="char" valign="top" char="." charoff="50">Â </td></tr><tr><td align="left" valign="top" charoff="50">FIGO I<hr></hr></td><td align="char" valign="top" char="(" charoff="50">86.7 (3.8)<hr></hr></td><td align="char" valign="top" char="." charoff="50">Â <hr></hr></td><td align="char" valign="top" char="(" charoff="50">91.9 (3.3)<hr></hr></td><td align="char" valign="top" char="." charoff="50">Â <hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">Grade<hr></hr></td><td align="char" valign="top" char="(" charoff="50">Â <hr></hr></td><td align="char" valign="top" char="." charoff="50">&lt;0.001<hr></hr></td><td align="char" valign="top" char="(" charoff="50">Â <hr></hr></td><td align="char" valign="top" char="." charoff="50">&lt;0.001<hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">G3</td><td align="char" valign="top" char="(" charoff="50">53.7 (8.6)</td><td align="char" valign="top" char="." charoff="50">Â </td><td align="char" valign="top" char="(" charoff="50">56.0 (11.1)</td><td align="char" valign="top" char="." charoff="50">Â </td></tr><tr><td align="left" valign="top" charoff="50">G2</td><td align="char" valign="top" char="(" charoff="50">75.7 (6.3)</td><td align="char" valign="top" char="." charoff="50">Â </td><td align="char" valign="top" char="(" charoff="50">78.5 (7.1)</td><td align="char" valign="top" char="." charoff="50">Â </td></tr><tr><td align="left" valign="top" charoff="50">G1<hr></hr></td><td align="char" valign="top" char="(" charoff="50">87.7 (4.5)<hr></hr></td><td align="char" valign="top" char="." charoff="50">Â <hr></hr></td><td align="char" valign="top" char="(" charoff="50">92.2 (3.8)<hr></hr></td><td align="char" valign="top" char="." charoff="50">Â <hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">Histological subtype<hr></hr></td><td align="char" valign="top" char="(" charoff="50">Â <hr></hr></td><td align="char" valign="top" char="." charoff="50">0.1<hr></hr></td><td align="char" valign="top" char="(" charoff="50">Â <hr></hr></td><td align="char" valign="top" char="." charoff="50">0.2<hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">Non-endometrioid</td><td align="char" valign="top" char="(" charoff="50">64.1 (10.5)</td><td align="char" valign="top" char="." charoff="50">Â </td><td align="char" valign="top" char="(" charoff="50">70.0 (12.4)</td><td align="char" valign="top" char="." charoff="50">Â </td></tr><tr><td align="left" valign="top" charoff="50">Endometrioid<hr></hr></td><td align="char" valign="top" char="(" charoff="50">76.5 (4.0)<hr></hr></td><td align="char" valign="top" char="." charoff="50">Â <hr></hr></td><td align="char" valign="top" char="(" charoff="50">80.8 (3.9)<hr></hr></td><td align="char" valign="top" char="." charoff="50">Â <hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">Age<hr></hr></td><td align="char" valign="top" char="(" charoff="50">Â <hr></hr></td><td align="char" valign="top" char="." charoff="50">0.09<hr></hr></td><td align="char" valign="top" char="(" charoff="50">Â <hr></hr></td><td align="char" valign="top" char="." charoff="50">0.6<hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">&gt;67.5 years</td><td align="char" valign="top" char="(" charoff="50">66.3 (6.2)</td><td align="char" valign="top" char="." charoff="50">Â </td><td align="char" valign="top" char="(" charoff="50">76.5 (5.8)</td><td align="char" valign="top" char="." charoff="50">Â </td></tr><tr><td align="left" valign="top" charoff="50">â©½67.5 years<hr></hr></td><td align="char" valign="top" char="(" charoff="50">82.3 (4.4)<hr></hr></td><td align="char" valign="top" char="." charoff="50">Â <hr></hr></td><td align="char" valign="top" char="(" charoff="50">82.3 (4.8)<hr></hr></td><td align="char" valign="top" char="." charoff="50">Â <hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">TSH<hr></hr></td><td align="char" valign="top" char="(" charoff="50">Â <hr></hr></td><td align="char" valign="top" char="." charoff="50">0.01<hr></hr></td><td align="char" valign="top" char="(" charoff="50">Â <hr></hr></td><td align="char" valign="top" char="." charoff="50">0.01<hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">&gt;2.5âmUâl<sup>â1</sup></td><td align="char" valign="top" char="(" charoff="50">49.9 (11.5)</td><td align="char" valign="top" char="." charoff="50">Â </td><td align="char" valign="top" char="(" charoff="50">57.7 (11.8)</td><td align="char" valign="top" char="." charoff="50">Â </td></tr><tr><td align="left" valign="top" charoff="50">â©½2.5âmUâl<sup>â1</sup><hr></hr></td><td align="char" valign="top" char="(" charoff="50">79.4 (3.6)<hr></hr></td><td align="char" valign="top" char="." charoff="50">Â <hr></hr></td><td align="char" valign="top" char="(" charoff="50">83.7 (3.7)<hr></hr></td><td align="char" valign="top" char="." charoff="50">Â <hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">Obesity<xref ref-type="fn" rid="t1-fn4">c</xref><hr></hr></td><td align="char" valign="top" char="(" charoff="50">Â <hr></hr></td><td align="char" valign="top" char="." charoff="50">0.3<hr></hr></td><td align="char" valign="top" char="(" charoff="50">Â <hr></hr></td><td align="char" valign="top" char="." charoff="50">0.07<hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">Yes</td><td align="char" valign="top" char="(" charoff="50">75.3 (5.2)</td><td align="char" valign="top" char="." charoff="50">Â </td><td align="char" valign="top" char="(" charoff="50">80.7 (5.6)</td><td align="char" valign="top" char="." charoff="50">Â </td></tr><tr><td align="left" valign="top" charoff="50">No<hr></hr></td><td align="char" valign="top" char="(" charoff="50">80.6 (6.7)<hr></hr></td><td align="char" valign="top" char="." charoff="50">Â <hr></hr></td><td align="char" valign="top" char="(" charoff="50">93.3 (4.6)<hr></hr></td><td align="char" valign="top" char="." charoff="50">Â <hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">Hypertension<xref ref-type="fn" rid="t1-fn5">d</xref><hr></hr></td><td align="char" valign="top" char="(" charoff="50">Â <hr></hr></td><td align="char" valign="top" char="." charoff="50">0.5<hr></hr></td><td align="char" valign="top" char="(" charoff="50">Â <hr></hr></td><td align="char" valign="top" char="." charoff="50">0.5<hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">Yes</td><td align="char" valign="top" char="(" charoff="50">78.8 (6.6)</td><td align="char" valign="top" char="." charoff="50">Â </td><td align="char" valign="top" char="(" charoff="50">91.6 (3.7)</td><td align="char" valign="top" char="." charoff="50">Â </td></tr><tr><td align="left" valign="top" charoff="50">No<hr></hr></td><td align="char" valign="top" char="(" charoff="50">76.4 (6.9)<hr></hr></td><td align="char" valign="top" char="." charoff="50">Â <hr></hr></td><td align="char" valign="top" char="(" charoff="50">84.2 (6.5)<hr></hr></td><td align="char" valign="top" char="." charoff="50">Â <hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">Diabetes mellitus<hr></hr></td><td align="char" valign="top" char="(" charoff="50">Â <hr></hr></td><td align="char" valign="top" char="." charoff="50">0.4<hr></hr></td><td align="char" valign="top" char="(" charoff="50">Â <hr></hr></td><td align="char" valign="top" char="." charoff="50">0.2<hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">Yes</td><td align="char" valign="top" char="(" charoff="50">74.0 (9.4)</td><td align="char" valign="top" char="." charoff="50">Â </td><td align="char" valign="top" char="(" charoff="50">78.3 (10.1)</td><td align="char" valign="top" char="." charoff="50">Â </td></tr><tr><td align="left" valign="top" charoff="50">No<hr></hr></td><td align="char" valign="top" char="(" charoff="50">82.5 (5.2)<hr></hr></td><td align="char" valign="top" char="." charoff="50">Â <hr></hr></td><td align="char" valign="top" char="(" charoff="50">90.1 (4.3)<hr></hr></td><td align="char" valign="top" char="." charoff="50">Â <hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">Study centre<hr></hr></td><td align="char" valign="top" char="(" charoff="50">Â <hr></hr></td><td align="char" valign="top" char="." charoff="50">0.3<hr></hr></td><td align="char" valign="top" char="(" charoff="50">Â <hr></hr></td><td align="char" valign="top" char="." charoff="50">0.1<hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">Vienna</td><td align="char" valign="top" char="(" charoff="50">78.2 (4.8)</td><td align="char" valign="top" char="." charoff="50">Â </td><td align="char" valign="top" char="(" charoff="50">84.8 (4.0)</td><td align="char" valign="top" char="." charoff="50">Â </td></tr><tr><td align="left" valign="top" charoff="50">Innsbruck</td><td align="char" valign="top" char="(" charoff="50">70.7 (5.7)</td><td align="char" valign="top" char="." charoff="50">Â </td><td align="char" valign="top" char="(" charoff="50">71.3 (6.9)</td><td align="char" valign="top" char="." charoff="50">Â </td></tr></tbody></table><table-wrap-foot><fn id="t1-fn1"><p>Abbreviations: FIGO=International Federation of Gynecology and Obstetrics; s.e.=standard error; TSH=thyroid-stimulating hormone.</p></fn><fn id="t1-fn2"><label>a</label><p>KaplanâMeier analysis (log-rank test).</p></fn><fn id="t1-fn3"><label>b</label><p>According to the 1988 FIGO stating system.</p></fn><fn id="t1-fn4"><label>c</label><p>Body mass index &gt;30âkgâm<sup>â2</sup>.</p></fn><fn id="t1-fn5"><label>d</label><p>Systolic blood pressure â©¾160 or diastolic blood pressure â©¾100 mmâHg.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl2"><label>Table 2</label><caption><title>Multivariable survival analyses</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"></col><col align="char" char="("></col><col align="char" char="."></col><col align="char" char="("></col><col align="char" char="."></col></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">Â <hr></hr></th><th colspan="2" align="center" valign="top" char="(" charoff="50"><bold>Disease-free survival</bold><hr></hr></th><th colspan="2" align="center" valign="top" char="(" charoff="50"><bold>Disease-specific survival</bold><hr></hr></th></tr><tr><th align="left" valign="top" charoff="50">Â </th><th align="center" valign="top" char="(" charoff="50"><bold>HR (95% CI)</bold></th><th align="center" valign="top" char="." charoff="50"><italic><bold>P</bold></italic><bold>-value</bold><xref ref-type="fn" rid="t2-fn2">a</xref></th><th align="center" valign="top" char="(" charoff="50"><bold>HR (95% CI)</bold></th><th align="center" valign="top" char="." charoff="50"><italic><bold>P</bold></italic><bold>-value</bold><xref ref-type="fn" rid="t2-fn2">a</xref></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Stage<xref ref-type="fn" rid="t2-fn3">b</xref>
(FIGO IV <italic>vs</italic> III <italic>vs</italic> II <italic>vs</italic> I)<hr></hr></td><td align="char" valign="top" char="(" charoff="50">2.2 (1.6â3.1)<hr></hr></td><td align="char" valign="top" char="." charoff="50">&lt;0.001<hr></hr></td><td align="char" valign="top" char="(" charoff="50">2.4 (1.6â3.6)<hr></hr></td><td align="char" valign="top" char="." charoff="50">&lt;0.001<hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">Grade
(G3 <italic>vs</italic> G2 <italic>vs</italic> G1)<hr></hr></td><td align="char" valign="top" char="(" charoff="50">1.6 (0.9â2.6)<hr></hr></td><td align="char" valign="top" char="." charoff="50">0.06<hr></hr></td><td align="char" valign="top" char="(" charoff="50">1.7 (0.9â3.1)<hr></hr></td><td align="char" valign="top" char="." charoff="50">0.05<hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">Age
(&gt;67.5 years <italic>vs</italic> â©½ 67.5 years)<hr></hr></td><td align="char" valign="top" char="(" charoff="50">1.8 (0.9â3.6)<hr></hr></td><td align="char" valign="top" char="." charoff="50">0.09<hr></hr></td><td align="char" valign="top" char="(" charoff="50">1.4 (0.6â3.3)<hr></hr></td><td align="char" valign="top" char="." charoff="50">0.4<hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">Histologic subtype
(non-endometrioid <italic>vs</italic> endometrioid)<hr></hr></td><td align="char" valign="top" char="(" charoff="50">0.6 (0.2â1.5)<hr></hr></td><td align="char" valign="top" char="." charoff="50">0.3<hr></hr></td><td align="char" valign="top" char="(" charoff="50">0.6 (0.1â1.9)<hr></hr></td><td align="char" valign="top" char="." charoff="50">0.4<hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">Study centre 
(Vienna <italic>vs</italic> Innsbruck)<hr></hr></td><td align="char" valign="top" char="(" charoff="50">1.2 (0.6â2.6)<hr></hr></td><td align="char" valign="top" char="." charoff="50">0.5<hr></hr></td><td align="char" valign="top" char="(" charoff="50">1.3 (0.5â3.3)<hr></hr></td><td align="char" valign="top" char="." charoff="50">0.5<hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">TSH
(&gt;2.5 <italic>vs</italic> â©½2.5âmUâl<sup>â1</sup>)</td><td align="char" valign="top" char="(" charoff="50">2.1 (0.9â4.8)</td><td align="char" valign="top" char="." charoff="50">0.057</td><td align="char" valign="top" char="(" charoff="50">2.7 (1.1â6.7)</td><td align="char" valign="top" char="." charoff="50">0.03</td></tr></tbody></table><table-wrap-foot><fn id="t2-fn1"><p>Abbreviations: 95% CI=95% confidence interval; FIGO=International Federation of Gynecology and Obstetrics; HR=hazard ratio; TSH=thyroid-stimulating hormone</p></fn><fn id="t2-fn2"><label>a</label><p>Cox regression model.</p></fn><fn id="t2-fn3"><label>b</label><p>According to the 1988 FIGO stating system.</p></fn></table-wrap-foot></table-wrap></floats-group></article>